Advertisement
Screener

GT BIOPHARMA, INC. (GTBP) Increase (Decrease) in Accounts Payable and Accrued Liabilities

2.8 / 5 stars · 68/120 Roast Me

GT BIOPHARMA, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities

GT BIOPHARMA, INC. (GTBP) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $537.00 thousand for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-10.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2021-12-29

  • GT BIOPHARMA, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2021-09-30 was $1.15M, a 3.99% increase year-over-year.
  • GT BIOPHARMA, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2021-06-30 was -$830.00K.
  • GT BIOPHARMA, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2021-03-31 was $219.00K, a 72.07% decline year-over-year.
  • GT BIOPHARMA, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2020-12-31 was -$2.00M, a 197.56% decline year-over-year.
  • GT BIOPHARMA, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2020 was -$838.00K, a 126.57% decline from fiscal 2019.
  • GT BIOPHARMA, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2019 was $3.15M, a 2219.12% increase from fiscal 2018.
  • GT BIOPHARMA, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2018 was $136.00K, a 90.37% decline from fiscal 2017.
  • GT BIOPHARMA, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2017 was $1.41M, a 49.80% decline from fiscal 2016.
Period endIncrease (Decrease) in Accounts Payable and Accrued Liabilities 3 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 3 month as first filedIncrease (Decrease) in Accounts Payable and Accrued Liabilities 6 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filedIncrease (Decrease) in Accounts Payable and Accrued Liabilities 9 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filedIncrease (Decrease) in Accounts Payable and Accrued Liabilities 12 month
2021-09-30$1.15M
derived: 10-Q 9 month − 10-Q/A 6 month · filed 2021-11-10
$318.00K
derived: sum of 2 quarters · filed 2021-12-29
$537.00K
10-Q · filed 2021-11-10
-$1.47M
derived: sum of 4 quarters · filed 2021-12-29
2021-06-30-$830.00K
derived: 10-Q/A 6 month − 10-Q 3 month · filed 2021-12-29
-$611.00K
10-Q/A · filed 2021-12-29
-$2.61M
derived: sum of 3 quarters · filed 2021-12-29
-$1.51M
derived: sum of 4 quarters · filed 2021-12-29
2021-03-31$219.00K
10-Q · filed 2021-05-17
-$1.78M
derived: sum of 2 quarters · filed 2021-05-17
-$680.00K
derived: sum of 3 quarters · filed 2021-11-10
-$1.40M
derived: sum of 4 quarters · filed 2021-12-29
2020-12-31-$2.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-04-16
-$899.00K
derived: sum of 2 quarters · filed 2021-11-10
-$1.62M
derived: sum of 3 quarters · filed 2021-12-29
-$838.00K
10-K · filed 2021-04-16
2020-09-30$1.10M
derived: 10-Q 9 month − 10-Q/A 6 month · filed 2021-11-10
$381.00K
derived: sum of 2 quarters · filed 2021-12-29
$1.17M
10-Q · filed 2021-11-10
$1.36M
10-Q · filed 2020-11-13
$3.22M
derived: sum of 4 quarters · filed 2021-12-29
2020-06-30-$723.00K
derived: 10-Q/A 6 month − 10-Q 3 month · filed 2021-12-29
$61.00K
10-Q/A · filed 2021-12-29
$261.00K
10-Q · filed 2020-08-14
$2.11M
derived: sum of 3 quarters · filed 2021-12-29
$3.19M
derived: sum of 4 quarters · filed 2021-12-29
2020-03-31$784.00K
10-Q · filed 2021-05-17
$1.42M
10-Q · filed 2020-05-15
$2.84M
derived: sum of 2 quarters · filed 2021-05-17
$3.91M
derived: sum of 3 quarters · filed 2021-05-17
$3.12M
derived: sum of 4 quarters · filed 2021-05-17
2019-12-31$2.05M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-04-16
$3.13M
derived: sum of 2 quarters · filed 2021-04-16
$2.34M
derived: sum of 3 quarters · filed 2021-04-16
$3.15M
10-K · filed 2021-04-16
2019-09-30$1.07M
derived: 10-Q 9 month − 10-Q/A 6 month · filed 2020-11-13
$284.00K
derived: sum of 2 quarters · filed 2020-11-13
$1.10M
10-Q · filed 2020-11-13
$1.29M
derived: sum of 4 quarters · filed 2020-11-13
2019-06-30-$791.00K
derived: 10-Q/A 6 month − 10-Q 3 month · filed 2020-08-18
$26.00K
10-Q/A · filed 2020-08-18
$215.00K
derived: sum of 3 quarters · filed 2020-08-18
$743.00K
derived: sum of 4 quarters · filed 2020-08-18
2019-03-31$817.00K
10-Q · filed 2020-05-15
$1.01M
derived: sum of 2 quarters · filed 2020-05-15
$1.53M
derived: sum of 3 quarters · filed 2020-05-15
$1.49M
derived: sum of 4 quarters · filed 2020-05-15
2018-12-31$189.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27
$717.00K
derived: sum of 2 quarters · filed 2020-03-27
$670.00K
derived: sum of 3 quarters · filed 2020-03-27
$136.00K
10-K · filed 2020-03-27
2018-09-30$528.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14
$481.00K
derived: sum of 2 quarters · filed 2019-11-14
-$53.00K
10-Q · filed 2019-11-14
-$521.00K
derived: sum of 4 quarters · filed 2019-11-14
2018-06-30-$47.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14
-$581.00K
10-Q · filed 2019-08-14
-$1.05M
derived: sum of 3 quarters · filed 2019-08-14
-$451.00K
derived: sum of 4 quarters · filed 2019-08-14
2018-03-31-$534.00K
10-Q · filed 2019-05-15
-$1.00M
derived: sum of 2 quarters · filed 2019-05-15
-$404.00K
derived: sum of 3 quarters · filed 2019-05-15
$355.00K
derived: sum of 4 quarters · filed 2019-05-15
2017-12-31-$468.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29
$130.00K
derived: sum of 2 quarters · filed 2019-03-29
$889.00K
derived: sum of 3 quarters · filed 2019-03-29
$1.41M
10-K · filed 2019-03-29
2017-09-30$598.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14
$1.36M
derived: sum of 2 quarters · filed 2018-11-14
$1.88M
10-Q · filed 2018-11-14
$2.29M
derived: sum of 4 quarters · filed 2018-11-14
2017-06-30$759.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14
$1.28M
10-Q · filed 2018-08-14
$1.69M
derived: sum of 3 quarters · filed 2018-08-14
$2.59M
derived: sum of 4 quarters · filed 2018-08-14
2017-03-31$523.00K
10-Q · filed 2018-05-15
$933.00K
derived: sum of 2 quarters · filed 2018-05-15
$1.83M
derived: sum of 3 quarters · filed 2018-05-15
$2.36M
derived: sum of 4 quarters · filed 2018-05-15
2016-12-31$410.00K
derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-03-01
$1.30M
derived: sum of 2 quarters · filed 2018-03-01
$1.84M
derived: sum of 3 quarters · filed 2018-03-01
$2.81M
10-K · filed 2018-03-01
2016-09-30$895.00K
derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2018-02-28
$1.43M
derived: sum of 2 quarters · filed 2018-02-28
$2.40M
10-Q/A · filed 2018-02-28
$2.26M
derived: sum of 4 quarters · filed 2018-02-28
2016-06-30$532.00K
derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2018-02-28
$1.51M
10-Q/A · filed 2018-02-28
$1.36M
derived: sum of 3 quarters · filed 2018-02-28
$2.12M
derived: sum of 4 quarters · filed 2018-02-28
2016-03-31$976.00K
10-Q/A · filed 2018-02-28
$833.00K
derived: sum of 2 quarters · filed 2018-02-28
$1.59M
derived: sum of 3 quarters · filed 2018-02-28
$1.86M
derived: sum of 4 quarters · filed 2018-02-28
2015-12-31-$143.00K
derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2018-02-28
$610.00K
derived: sum of 2 quarters · filed 2018-02-28
$886.00K
derived: sum of 3 quarters · filed 2018-02-28
$880.00K
10-K/A · filed 2018-02-28
2015-09-30$753.00K
derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2018-02-28
$1.03M
derived: sum of 2 quarters · filed 2018-02-28
$1.02M
10-Q/A · filed 2018-02-28
$416.00K
derived: sum of 4 quarters · filed 2018-02-28
2015-06-30$276.00K
derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2018-02-28
$270.00K
10-Q/A · filed 2018-02-28
-$337.00K
derived: sum of 3 quarters · filed 2018-02-28
-$185.00K
derived: sum of 4 quarters · filed 2018-02-28
2015-03-31-$6.00K
10-Q/A · filed 2018-02-28
-$613.00K
derived: sum of 2 quarters · filed 2018-02-28
-$461.00K
derived: sum of 3 quarters · filed 2018-02-28
-$366.00K
derived: sum of 4 quarters · filed 2018-02-28
2014-12-31-$607.00K
derived: 10-K/A 12 month − 10-Q 9 month · filed 2018-02-28
-$455.00K
derived: sum of 2 quarters · filed 2018-02-28
-$360.00K
derived: sum of 3 quarters · filed 2018-02-28
-$276.00K
10-K/A · filed 2018-02-28
2014-09-30$152.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13
$247.00K
derived: sum of 2 quarters · filed 2015-11-13
$331.00K
10-Q · filed 2015-11-13
$366.00K
derived: sum of 4 quarters · filed 2015-11-13
2014-06-30$95.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14
$179.00K
10-Q · filed 2015-08-14
$214.00K
derived: sum of 3 quarters · filed 2015-08-14
$375.00K
derived: sum of 4 quarters · filed 2015-08-14
2014-03-31$84.00K
10-Q · filed 2015-05-14
$119.00K
derived: sum of 2 quarters · filed 2015-05-14
$280.00K
derived: sum of 3 quarters · filed 2015-05-14
$403.00K
derived: sum of 4 quarters · filed 2015-05-14
2013-12-31$35.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-31
$196.00K
derived: sum of 2 quarters · filed 2015-03-31
$319.00K
derived: sum of 3 quarters · filed 2015-03-31
$480.00K
10-K · filed 2015-03-31
2013-09-30$161.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-01-08
$284.00K
derived: sum of 2 quarters · filed 2015-01-08
$445.00K
10-Q · filed 2015-01-08
-$700.00K
derived: sum of 4 quarters · filed 2015-01-08
2013-06-30$123.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-01-08
$284.00K
10-Q · filed 2015-01-08
-$861.00K
derived: sum of 3 quarters · filed 2015-01-08
-$892.00K
derived: sum of 4 quarters · filed 2015-01-08
2013-03-31$161.00K
10-Q · filed 2015-01-08
-$984.00K
derived: sum of 2 quarters · filed 2015-01-08
-$1.01M
derived: sum of 3 quarters · filed 2015-01-08
$651.00K
derived: sum of 4 quarters · filed 2015-01-08
2012-12-31-$1.15M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-01-08
-$1.18M
derived: sum of 2 quarters · filed 2015-01-08
$490.00K
derived: sum of 3 quarters · filed 2015-01-08
$605.00K
10-K · filed 2015-01-08
2012-09-30-$31.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-12-17
$1.64M
derived: sum of 2 quarters · filed 2014-12-17
$1.75M
10-Q · filed 2014-12-17
$1.62M
derived: sum of 4 quarters · filed 2014-12-17
2012-06-30$1.67M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-12-12
$1.78M
10-Q · filed 2014-12-12
$1.65M
derived: sum of 3 quarters · filed 2014-12-12
$2.07M
derived: sum of 4 quarters · filed 2014-12-12
2012-03-31$115.00K
10-Q · filed 2014-12-10
-$19.00K
derived: sum of 2 quarters · filed 2014-12-10
$402.00K
derived: sum of 3 quarters · filed 2014-12-10
-$1.01M
derived: sum of 4 quarters · filed 2014-12-10
2011-12-31-$134.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-11-18
$287.00K
derived: sum of 2 quarters · filed 2014-11-18
-$1.13M
derived: sum of 3 quarters · filed 2014-11-18
$533.00K
10-K · filed 2014-11-18
2011-09-30$421.00K
derived: 10-Q 9 month − 10-Q/A 6 month · filed 2012-11-21
-$993.00K
derived: sum of 2 quarters · filed 2012-11-21
$667.00K
10-Q · filed 2012-11-21
$586.00K
derived: sum of 4 quarters · filed 2012-11-21
2011-06-30-$1.41M
derived: 10-Q/A 6 month − 10-Q 3 month · filed 2012-09-13
$246.00K
10-Q/A · filed 2012-09-13
$165.00K
derived: sum of 3 quarters · filed 2012-09-13
$216.00K
derived: sum of 4 quarters · filed 2012-09-13
2011-03-31$1.66M
10-Q · filed 2012-05-21
$1.58M
derived: sum of 2 quarters · filed 2012-05-21
$1.63M
derived: sum of 3 quarters · filed 2012-05-21
2010-12-31-$81.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2012-04-16
-$30.00K
derived: sum of 2 quarters · filed 2012-04-16
$154.00K
10-K · filed 2012-04-16
2010-09-30$51.00K
derived: 10-Q 9 month − 10-Q/A 6 month · filed 2011-11-21
$235.00K
10-Q · filed 2011-11-21
2010-06-30$184.00K
10-Q/A · filed 2011-09-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
ABEONA THERAPEUTICS INC. (ABEO)United States$0.312B-5.63
Vanda Pharmaceuticals Inc. (VNDA)United States$0.302B-1.35
Prelude Therapeutics Inc (PRLD)United States$0.318B-7.01
Evommune, Inc. (EVMN)United States$0.320B-5.10
STANDARD BIOTOOLS INC. (LAB)United States$0.297B3.80
BridgeBio Oncology Therapeutics, Inc. (BBOT)United States$0.320B-3.35
ROCKET PHARMACEUTICALS, INC. (RCKT)United States$0.296B-21.78
Fulcrum Therapeutics, Inc. (FULC)United States$0.289B-3.28
Contineum Therapeutics, Inc. (CTNM)United States$0.289B-4.40
BioAge Labs, Inc. (BIOA)United States$0.333B-11.88